Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance Post-ASCT for High-Risk NHL
NCT01035463Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Nov 2009
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in non-Hodgkin lymphoma (NHL), sponsored by University of Nebraska. Primary endpoint: Maximum Tolerated Dose of Lenalidomide. Started Nov 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01035463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035463.